Individual drugs associated with overweight inducing


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Drug-induced weight gain is a serious side effect of many drugs, leading to non-compliance with the correct treatment regimen and exacerbation of concomitant chronic diseases associated with obesity and increased body weight. This undesirable drug reaction affects the increase in blood pressure, the normal functioning of the musculoskeletal system, impaired lipid profile, as well as impaired glucose control. The use of sugar-lowering drugs such as insulin, sulfonylurea preparations (glyclazide, glimepiride, glibenclamide) and thiazolidinediones (pioglitazone, rosiglitazone) is usually accompanied by increased weight. Weight gain can be reduced or prevented with a low-calorie diet and regular exercise or combination therapy with metformin. Weight gain is also common with psychotropic therapy. It is known that both atypical antipsychotics (clozapine, olanzepine, risperidone, quetiapine and others), as well as classical ones (haloperidol, chlorpromazine, thioridazine) cause a noticeable increase in weight. Many antidepressants, such as amitriptyline, the world and the body, and some other serotonin reuptake inhibitors and monoamine oxidase inhibitors can also contribute to significant weight gain, which cannot be explained only by increased symptoms of depression. Antiepileptic drugs that promote weight gain include valproate, carbamazepine and gabapentin. The same side effect is observed with hormonal, antihypertensive, chemotherapeutic drugs. Therefore, when prescribing to the patient, it is necessary to use the medications necessary for weight gain. This is especially important for patients with a high body mass index.

Texto integral

Acesso é fechado

Sobre autores

Olga Ostroumova

Russian Medical Academy of Continuous Professional Education; I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: ostroumova.olga@mail.ru
Dr. Sci. (Med.), Professor, Department of Therapy and Polymorbid Pathology

Yu. Sapozhnikova

A.I. Yevdokimov Moscow State University of Medicine and Dentistry

A. Kochetkov

Russian Medical Academy of Continuous Professional Education

A. Starodubova

Federal Research Centre of Nutrition, Biotechnology and Food Safety (Federal Research Centre of Nutrition and Biotechnology); Pirogov Russian National Research Medical University

Bibliografia

  1. Sheehan A.H. Chapter 53: Weight Gain. In: Tisdale J.E. and Miller D.A. Drug-Induced Diseases: prevention, detection, and management. 3rd ed. ASH, 2018. Р 1171-77.
  2. Wharton S., Raiber L, Serodio K.J., et al. Medications that cause weight gain and alternatives in Canada: a narrative review. Diab Metab Syndr Obes. 2018;11:427-38. doi: 10.2147/DMSO.S171365.
  3. Lampl Y, Eshel Y, Rapaport A., Sarova-Pinhas I. Weight gain, increased appetite, and excessive food intake induced by carbamazepine. Clin Neuropharmacol. 1991;14(3):251-55. doi: 10.1097/00002826-199106000-00009.
  4. Corman C.L., Leung N.M., Guberman A.H. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci. 1997:24(3):240-44. Doi: 10.1017/ s0317167100021879.
  5. Hogan R.E., Bertrand M.E., Deaton R.L., Sommerville K.W. Total percentage body weight changes during add-on therapy with tiagabine, carbamazepine, and phenytoin. Epilepsy Res. 2000;41(1):23-8. doi: 10.1016/s0920-1211(00)00125-x.
  6. Chen C.H., Lin S.K. Carbamazepine treatment of bipolar disorder: a retrospective evaluation of naturalistic long-term outcomes. BMC. Psychiatry. 2012;12:47. doi: 10.1186/1471-244X-12-47.
  7. Beydoun A., Fischer J, Labar D.R., etal. Gabapentin monotherapy: a 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. Neurology. 1997;49(49):746-52. Doi: 10.1212/ wnl.49.3.746.
  8. Baulac M., Calvacanti D., Semah F, et al. Gabapentin add-on therapy with adaptable dosages in 610 patients with partial epilepsy: an open, observation study. Seizure. 1998;7(1):55-62. doi: 10.1016/s1059-1311(98)90009-7.
  9. DeToledo J.C., Toledo C., De Cerce J., Ramsay R.E. Changes in body weight with chronic, high dose gabapentin therapy. Ther Drug Monit. 1997;19(4):394-96. doi: 10.1097/00007691199708000-00006.
  10. Jensen M.P, Irving G., Rauck R., et al. Long-term safety of gastroretentive gabapentin in postherpetic neuralgia patients. Clin J Pain. 2013;29(9):770-74. doi: 10.1097/AJP.0b013e31827b32ab.
  11. Lyrica package insert. New York, NY: Parke-Davis Division of Pfizer Inc; 2016.
  12. Beydoun A.M., Uthman B.M., Kugler A.R., et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology. 2005;64(3):475-80. doi: 10.1212/01. WNL.0000150932.48688.BE
  13. Carreno M., Maestro I., Molins A., et al. Pregabalin as add-on therapy for refractory partial seizures in every day clinical practice. Seizure. 2007;16(8):709-12. doi: 10.1016/j.seizure.2007.05.011.
  14. Hoppe C., Rademacher M., Hoffmann J.M. Bodyweight gain under pregabalin therapy in epilepsy: mitigation by counseling patients? Seizure. 2008;17(4):327-32. Doi: 10.1016/j. seizure.2007.10.004.
  15. Siddall PJ., Cousins M.J., Otte A., et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2007;67(10):1792-800. doi: 10.1212/01. wnl.0000244422.45278.1f.
  16. Jallon P, Picard F. Body weight gain and anticonvulsants: a comparative review. Drug Saf. 2001;24(13):969-78. doi: 10.2165/00002018200124130-00004.
  17. Tzellos T.G., Toulis K.A., Goulis D.G., et al. Gabapentin and pregabalin in the treatment of, fibromyalgia: a systematic review and a meta-analysis. J Clin Pharm Ther 2010;35(6):639-56. doi: 10.1111/j.1365-2710.2009.01144.x.
  18. Chen B., Choi H., Hirsch L.J., et al. Cosmetic side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2015;42:129-37. Doi: 10.1016/j. yebeh.2014.10.021.
  19. Dinesen J., Lennart G., Andersen T., Dam M. Weight gain during treatment with valproate. Acta Neurol Scand. 1984;70(2):65-9. doi: 10.1111/j.1600-0404.1984.tb00804.x.
  20. Mattson H., Cramer J.A., Collins J.F A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. N Engl Med. 1992;327(11):765-71. Doi: 10.1056/ NEJM199209103271104.
  21. Isojarvi J.I.T, Laatikainen T.H., Knip M., et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol. 1996;39(5):579-84. doi: 10.1002/ana.410390506.
  22. Biton V, Mirza W., Montouris G., et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001;56(2):172-77. doi: 10.1212/wnl.56.2.172.
  23. Privitera M.D, Brodie M.H., Mattson R.H., et al. EPMN 105 Study Group. Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand. 2003;107(3):165-75. doi: 10.1034/j.1600-0404.2003.00093.x.
  24. Pickrell W.O., Lacey A.S., Thomas R.H., et al. Weight change associated with antiepileptic drugs. J Neurol Neurosurg Psychiatry. 2013;84(7):796-99. doi: 10.1136/jnnp-2012-303688.
  25. Petty S.J., Kantor S., Lawrence K.M., et al. Weight and fat distribution in patients taking valproate: a valproate-discordant gender-matched twin and sibling pair study. Epilepsia. 2014;55(10):1551-57. doi: 10.1111/epi.12745.
  26. Kanemura H., Sano F, Maeda Y, et al. Valproate sodium enhances body weight gain in patients with childhood epilepsy: a pathogenic mechanisms and open-label clinical trial of behavior therapy Seizure. 2012;21(7):496-500. Doi: 10.1016/j. seizure.2012.05.001.
  27. Garland E., Remich R.A., Zis A. Weight gain with antidepressants and lithium. J Clin Psychopharmacol. 1988;8(5):323-30.
  28. Szarek B.L., Brandt D.M. A comparison of weight changes with fluoxetine, desipramine, and amitriptyline: a retrospective study of psychiatric inpatients J Nerv Ment Dis. 1993;181(11):702-4. doi: 10.1097/00005053-199311000-00010.
  29. Yeragani V.K., Pohl R., Aleem A., et al. Carbohydrate craving and increased appetite associated with antidepressant therapy. Can J Psychiatry. 1988;33:606-10. doi: 10.1177/070674379303800106.
  30. Paykel E.S., Mueller PS., De La Vergne PM. Amitriptyline, weight gain and carbohydrate craving: A side effect. Br J Psychiatry. 1973;123(576):501 7. doi: 10.1192/bjp.123.5.501
  31. Hecht-Orzack M., Cole J.O., Friedman L., et al. Weight changes in antidepressants: a comparison of amitriptyline and trazodone. Neuropsychobiol. 1986;15(1):28-30. doi: 10.1159/000118237.
  32. Pande A.C., Grunhaus L.J., Haskett R.F., Greden J.F Weight change with antidepressant treatment. Biological. Psychiatry. 1989;25:A55.
  33. Montgomery S.A., Reimitz PE., Zivkoz M. Mirtazapine versus amitriptyline in long-term treatment of depression: a double-blind placebo-controlled study Int Clin Psychopharmacol. 1998;13(2):63-73. doi: 10.1097/00004850-199803000-00002.
  34. Wade A., Overo K.F, lemming O., et al. Weight monitoring during two long-term trials of citalopram. Presented at the 12th Congress of the European College of Neuropsychopharmacol. London, England, 1999.
  35. Calegari L., Gorenstein C., Gentil V, et al. Effect of Chronic Treatment with Clomipramine on Food Intake, Macronutrient Selection and Body Weight Gain in Rats. Biological & Pharmaceutical Bulletin. 2007;30(8):1541-46. Doi: 10.1248/ bpb.30.1541.
  36. Fernstrom M.H., Krowinski R.L., Kupfer D.J. Chronic imipramine treatment and weight gain. Psychol Res. 1986;17(4):269-73. doi: 10.1016/0165-1781(86)90074-0.
  37. Blumenthal S.R., Castro V.M., Clements C.C., et al. An electronic health records study of long-term weight gain following antidepressant use. JAMA. Psychiatry. 2014;71(8):889-96. Doi: 10.1001/ jamapsychiatry.2014.414.
  38. Remeron package insert. West Orange, N.J. Оrganon, USA Inc; 2015.
  39. Nelson J.C., Pritchett Y.L., Martynov O., et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion. J Clin Psychiatry. 2006;8(4):212-19. doi: 10.4088/pcc.v08n0404.
  40. Hou Y.C., Lai C.H. Bupropion-related weight gain in a fresh depression patient. J Neuropsych Clin Neurosci. 2014;26(2):E52-3. doi: 10.1176/appi. neuropsych.13050107.
  41. Laimer M., Kramer-Reinstadler K., Rauchenzauner M., et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry. 2006;67(3):421-24. doi: 10.4088/jcp.v67n0313.
  42. Uguz F, Sahingoz M., Gungor B., et al. Weight gain and associated factors in patients using newer antidepressants. Gen Hosp Psychiatry. 2015;37(1):46-8. Doi: 10.1016/j. genhosppsych.2014.10.011.
  43. Rabkin J., Quitkin F, Harrison W., et al. Adverse reactions to monoamine oxidase inhibitors: part I. A comparative study. J Clin Psychopharmacol. 1984;4(4):270-78.
  44. Allison D.B., Mentore J.L., Heo М., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686 96. doi: 10.1176/ajp.156.11.1686
  45. Briffa D., Meehan T. Weight changes during clozapine treatment. Aust N Z J Psychiatry. 1998;32(5):718 21. Doi: 10.3109%2F00048679809113128
  46. Lamberti S., Terrance B., Schwarzkopt F. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry. 1992;149(5):689-90. doi: 10.1176/ajp.149.5.689.
  47. Bustillo J.R., Buchanan R.W., Irish D., A Breier. Differential effect of clozapine on weight: a controlled study. Am J Psychiatry. 1996;153(6):817-19. doi: 10.1176/ajp.153.6.817.
  48. Cohen S., Chiles J., MacNauthton A. Weight gain associated with clozapine. Am. J. Psychiatry. 1990;147(4):503-4. Doi: 10.1176/ ajp.147.4.503.
  49. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf. 2006;29(4):303-19. doi: 10.2165/00002018-200629040-00002.
  50. Theisen F.M., Cichon S., Linden M.M., et al. Clozapine and weight gain. Am J Psychiatry. 2001;158:816. doi: 10.1176/appi.ajp.158.5.816.
  51. Leadbetter R., Shutty M., Pavalonis D., et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry. 1992;149(1):68 72. doi: 10.1176/ajp.149.1.68
  52. Bak M., Fransen A., Janssen J., et al. Almost all antipsychotics result in weight gain: a meta-analysis. PloS. One. 2014;9(4):e94112. Doi: 10.1371/ journal.pone.0094112
  53. Kerry R.J., Liebling L., Owen G. Weight changes in responders. Acta PsychiatrScand. 1970;46:238-43.
  54. Vendsborg P, Bech P, Rafaelsen O. Lithium treatment and weight gain. Acta Psychiatr Scand. 1976;53(5):139-47. doi: 10.1111/j.1600-0447.1976.tb00067.x.
  55. Peselow E.D, Dunner D.L., Fieve R.R., Lautin A. Lithium carbonate and weight gain. J Affect Disord. 1980;2(4):303-10. doi: 10.1016/0165-0327(80)90031-2.
  56. Tate T, Willig A.L., Willig J.H., et al. HIV infection and obesity: where did all the wasting go? Antivir Ther. 2012;17(7):1281-89. doi: 10.3851/IMP2348.
  57. Erlandson K.M., Kitch D., Tierney C., et al. Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS. 2013;24;27(13):2069-79. Doi: 10.1097/ QAD.0b013e328361d25d.
  58. Lakey W, Yang L.Y., Yancy W., et al. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS. Res Hum Retrovir. 2013;29(3):435 40. doi: 10.1089/aid.2012.0234
  59. Dixon J, Moritz D., Baker F. Breast cancer and weight gain: an unexpected finding. Oncol Nurs Forum. 1978;5(3):5-7.
  60. Heasman K.Z., Sutherland H.J., Campbell J.A., et al. Weight gain during adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 1985;5(2):195-200. doi: 10.1007/BF01805994.
  61. Huntington M.O. Weight gain in patients receiving adjuvant chemotherapy for carcinoma of the breast. Cancer. 1985;56:472-74. doi: 10.1002/1097-0142(19850801)56:3%3C4 72:AID-CNCR2820560310%3E3.0.CO;2-3.
  62. Chlebowski R.T., Weiner J.M., Reynolds R., et al. Long-term survival following relapse after 5-FU, but not CMF adjuvant breast cancer therapy. Breast Cancer Res Treat. 1986;7(1):23-9. Doi: 10.1007/ BF01886732.
  63. Freedman R.J., Aziz N., Albanes D., et al. Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. J Clin Endocrinol Metab. 2004;89(5):2248-53. doi: 10.1210/jc.2003-031874.
  64. Demling R.H., DeSanti L. Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns. J Trauma. 1997;43(1):47-51. doi: 10.1097/00005373199707000-00012.
  65. Karcic E., Philpot C., Morley J.E. Treating malnutrition with megestrol acetate: literature review and review of our experience. Nutr Health Aging. 2002;6(3):191-200.
  66. Mwamburi D.M., Gerrior J., Wilson I.B., et al. Combination megestrol acetate, oxandrolone, and dietary advice restores weight in human immunodeficiency virus. Nutr Clin Pract. 2004;19(4):395-402. doi: 10.1177/0115426504019004395.
  67. Cuerda C., Zugasti A., Breton I., et al. Treatment with nandrolone decanoate and megestrol acetate in HIV-infected men. Nutr Clin Pract. 2005;20(1):93-7. doi: 10.1177/011542650502000193.
  68. Kyle V, Hazleman B.L. Treatment of polymyalgia rheumatica and giant cell arteritis: relation between steroid dose and steroid associated side effects. Ann Rheum Dis. 1989;48(8):662-66. Doi: 10.1136/ ard.48.8.662.
  69. Prummel M.F., Mourits M.P, Blank L., et al. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy Lancet. 1993;342(8877):949-54. doi: 10.1016/0140-6736(93)92001-A.
  70. Horber F.F., Zurcher R.M., Herren H., et al. Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. Am J Clin Nutr. 1986;43:758-69. Doi: 10.1093/ ajcn/43.5.758.
  71. Pelkman C. Hormones and weight change. J Reprod Med. 2002;47(Suppl.):791-4.
  72. Mangan S.A., Larsen PG., Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2002;15(2):79 82. doi: 10.1016/S1083-3188(01) 00147-4
  73. Montanana C.F., Herrero C.H., Fernandez M.R. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients - the PREDICTIVETM BMI clinical trial. Diab Med. 2008;25(8):916-23. doi: 10.1111/j.1464 5491.2008.02483.x
  74. Hermansen K., Mortensen L.S. Bodyweight changes associated with antihyperglycemic agents in type 2 diabetesmellitus. DrugSaf. 2007;30(12):1127-42. doi: 10.2165/00002018-200730120-00005.
  75. Actos package insert, Deerfield, IL: Takeda Pharmaceuticals America Inc; 2013.
  76. Avandia package insert, Research Triangle Park, NC: GlaxoSmithKline; 2014.
  77. Domecq J.P, Prutsky G., Leppin A., et al. Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(2):363-70. Doi: 10.1210/ jc.2014-3421.
  78. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427 43. doi: 10.1056/NEJMoa066224
  79. Clarke B.F., Campbell I.W. Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. Br Med J. 1977;2(6102): 1576-78. Doi: 10.1136/ bmj.2.6102.1576.
  80. Marbury T., Huang W.C., Strange P., Lebovitz H. Repaglinide versus glyburide: a one-year comparison trial. Diab Res Clin Pract. 1999; 43:155-66.
  81. Tan M.H., Baksi A., Krahulec B., et al.; for the GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diab Care. 2005;28(3):544-50. Doi: 10.2337/ diacare.28.3.544
  82. Jovanovic L., Hassman D.R., Gooch B., et al. Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diab Res Clin Pract. 2004;63(2):127-34. Doi: 10.1016/j. diabres.2003.09.004
  83. Messerli F.H., Bell D.S., Fonseca V., et al.; GEMINI Investigators. Body weight changes with beta-blocker use: results from GEMINI. Am J Med. 2007;120(7):610-15. Doi: 10.1016/j. amjmed.2006.10.017

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2020

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies